1. A phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). (December 2016) Authors: Byers, L.; Gerber, D.; Peguero, J.; Micklem, D.; Yule, M.; Lorens, J.B. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗